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ABSTRACT
This review aims to evaluate the role of anaesthetics, steroids and platelet-rich plasma (PRP) employed with ultrasound-
guided injection in the management of musculoskeletal pathology of the extremities. Ultrasound-guided injection represents
an interesting and minimally invasive solution for the treatment of tendon and joint inflammatory or degenerative diseases.
The availability of a variety of new drugs such as hyaluronic acid and PRP provides expansion of the indications and
therapeutic possibilities. The clinical results obtained in terms of pain reduction and functional recovery suggest that the use
of infiltrative procedures can be a good therapeutic alternative in degenerative and inflammatory joint diseases.
INTRODUCTION
In the ﬁeld of musculoskeletal diseases, inﬁltrative
ultrasound-guided therapy is an effective treatment
option.1–4 This technique, nowadays, is increasingly being
used in the treatment of diseases of the musculoskeletal
system, owing to its minimally invasive approach, low
anaesthesiological risk and the continuous advancements
in materials and imaging equipment. The imaging guide is
not necessary for inﬁltrative procedures, and many spe-
cialists are currently doing without; nevertheless, for radi-
ologists, it represents an added value and is essential to
provide the patient with safe and accurate treatments. Es-
pecially in the treatment of superﬁcial lesions involving the
soft tissues, ultrasound is an excellent leading technique,
providing the operator with multiplanar and dynamic
images of the examined structures; it also allows reaching
the target structure with precision, avoiding damage to
important anatomical structures (vessels, nerves etc.). This
technique is operator dependent and requires a thorough
knowledge of the anatomy and a good experience in di-
agnostic ultrasound imaging.2–4
INFILTRATIVE TECHNIQUES
The ultrasound-guided approach can be performed with
different techniques.
Free-hand technique with axial or parallel access
This technique requires good manual skill from the oper-
ator, who must be able to coordinate the transducer and
needles in real time and with both hands. It is especially
indicated for the treatment of superﬁcial sites. To visualize
the needle, two conditions are required:
• To be visible to the operator, the needle must be
introduced within the ﬁeld of view of the transducer.
• To be visualized, the inclination of the needle, with
respect to the transducer, must range from 60° to 90°.
Between 0° and 60°, the needle will not be visible.3,4
Parallel access
In parallel access, the needle is introduced parallel to the
transducer. This approach is used speciﬁcally in the treat-
ment of tendon and bursal disease of the shoulder, in
epicondylitis and in the patellar and Achilles tendons.
Axial access
Axial access can be performed only by free hand, in any
anatomical site, both deep and superﬁcial. The target area
should be positioned at the centre of the image and the
needle should be introduced in a point exactly in the
middle of the largest side of the transducer, more or less
vertically to the depth of the target. In this technique, the
operator cannot see the needle when it is ﬁrst introduced,
but only in the ﬁnal stage when the needle reaches the target.
This access is useful in anatomical sites where the proximity to
important structures, such as vessels and nerves, does not allow
the parallel orientation of the needle with respect to the trans-
ducer. In some cases, it could be helpful to perform these
techniques with a combined approach.
Ultrasound-guided approach with pointing kit
This approach uses a pointing kit, applied on the transducer,
which allows locating the needle perfectly by following the path
on the ultrasound monitor. The guides can be angle ﬁxed or
multiangle (and are selected depending on the depth of the
target). The advantage of using such a device is correlated to the
ability to have a good view of the needle even when its in-
clination with regard to the ultrasound beam is not optimal. The
application of the guide may be useful when inﬁltrating deep
structures such as the hip. However, it has some drawbacks
related to longer times of preparation and the need to use longer
needles that can be manoeuvred from the outside.3,4
PATIENT SELECTION CRITERIA
The patient will be recruited for the interventional procedure
only after a careful selection and a correct assessment of his/her
conditions. For each disease, it is necessary to carry out a series
of preliminary tests, such as clinical and laboratory tests and
diagnostic examinations. Only subsequently, the most appro-
priate treatment can be carried out.
Inﬁltrative articular and para-articular therapies, however, are an
invasive act, and as such require informed consent from the
patient and the respect of the rules of asepsis from the inter-
ventional radiologist and his team.3,4 Informed consent is useful
to establish a relationship of respect and trust between the
doctor and the patient, a guided path of information through
communication.
Sterility rules must be part of the knowledge of the interven-
tional radiologist, because the greatest risk is that of septic joint
inﬂammation. A sterile ﬁeld setup is needed, with sterile gauze
and the correct solution for disinfecting the skin (active in-
gredient: povidone iodine), sterile probe cover, sterile gel and
disposable syringes of different sizes depending on the needs of
the operator.
The diseases that are most frequently treated with musculo-
skeletal interventional radiology of the extremities are osteoar-
thritis, chondropathies, joint pain from chronic friction and
overload, bursitis, synovitis and insertional tendinopathy.
LOCAL ANAESTHETICS
Pharmacological aspects
Local anaesthetics are drugs that express their analgesic effect by
reversibly interrupting nerve conduction in the administration
site. Their mechanism of action is supposed to be nerve con-
duction blockade, interrupting the propagation of the action
potential along axons through the sodium channel blockade
(sodium channels are normally present in the lipid bilayer of the
plasma membrane). When the neuron is stimulated, the sodium
channel state changes from inactive to active, allowing the
passage of sodium ions and the beginning of depolarization.
Local anaesthetics have a great afﬁnity for certain receptors of
sodium channels during the transition between active and in-
active status. Local anaesthetics are a very heterogeneous class of
compounds and can be divided into two categories: amino esters
(procaine, chloroprocaine and tetracaine) and amino amides
(prilocaine, etidocaina, lidocaine, mepivacaine, bupivacaine,
ropivacaine and levobupivacaine), based on the type of bond of
their intermediate chain.
The drugs, the most commonly used are listed below.
Lidocaine
Lidocaine is used more for its rapid absorption and onset; the
effect lasts about 3 h. Its acid dissociation constant (pKa) of 7.7
allows rapid distribution to the extremities.
Mepivacaine
Mepivacaine has a pKa of 7.6 and a lower activity than lidocaine
but slower absorption. The half-life is about 2–4 h. It also
presents vasospasm effect, in contrast to other local anaesthetics.
The administration form is a white powder soluble in water. In
addition, a factor that should not be underestimated is that
mepivacaine has no vasodilator effect, so it does not need the
combined administration of a vasoconstrictor agent.
Bupivacaine
Bupivacaine has a pKa of 8.1. Its effects are similar to those of
mepivacaine, but it possesses a long duration, up to 18–24 h,
with slow absorption. At low doses, it predominantly has sen-
sory blockade rather than motor blockade. It also has greater
toxicity.5
Ropivacaine
Ropivacaine is a local anaesthetic of the amide type with a chemical
structure similar to bupivacaine and mepivacaine. The physical and
chemical properties are similar to those of bupivacaine. In vitro
ropivacaine has fewer adverse neurotoxic and cardiotoxic effects.
Compared with bupivacaine, ropivacaine has (at the same serum
concentration) less motor blockade at low concentrations, less
cardiac toxicity and lower lipid solubility. An interesting property of
ropivacaine is the low vasodilatatory effect.
Procaine
Procaine is a water-soluble drug that has a rapid absorption
from the injection site and is hydrolyzed in para-aminobenzoic
acid by a plasmic esterase.6
When and how
If the procedure is locally painful, local anaesthetics can be used,
inﬁltrating the skin at the site of surgery.3,4 The use of anaes-
thetics with an average duration of action allows for adequate
coverage of pain and to some degree contributes to the patient
comfort level in the following hours.7,8
Complications
The toxicity mediated by these drugs depends on the direct sys-
temic effect, which from its site of administration moves in
a circle, reaching the central and peripheral nervous system and
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the cardiovascular system. Surely, the most serious side effect is
represented by seizures. In addition to the nerve blockade, the role
of local anaesthetics includes varying degrees of vasodilation and
this contributes to the hypotension observed after administration
of large doses of the drug. If the plasma concentration of the local
anaesthetic continues to rise, it could lead to coma, respiratory
arrest and possibly cardiovascular collapse. While it has been
observed that most of the local anaesthetics have similar toxic
effects on the central nervous system, it is interesting to note that
bupivacaine has more adverse effects on the cardiovascular sys-
tem. This concept turns out to be of enormous importance in all
those procedures where bupivacaine is administered at high doses
and in patients with predisposition to heart disease.
Apart from major side effects, there are minor effects including
tremors, disorientation, dizziness, mydriasis, increased metab-
olism and body temperature, sweating, nausea and vomiting,
bronchospasm, laryngeal oedema and respiratory collapse. The
local manifestations may include rashes of various types, urti-
carial rash and pruritus. The ﬁrst sign of systemic toxicity is
drowsiness or a sense of sensory dulling, followed by lingual
paraesthesia, tinnitus, visual disturbances and agitation. In se-
vere poisonings, convulsions, coma and cardiorespiratory de-
pression may occur. We can also witness rhythm disturbances,
e.g. ventricular extra systoles, ventricular and supraventricular
tachycardia and conduction defects.
Allergies to local anaesthetics are rare. Patients often report allergy
to local anaesthetics, syncope or palpitations, events attributable to
more adrenaline added to the solution or endogenously released
in response to stress. Other reactions may be due to hypersensi-
tivity to preservatives (methylparaben) and antioxidants dissolved
in the solution, which serve to prevent microbial growth, while
antioxidants prevent the oxidation of adrenaline. The allergic
reactions are due to the activation of sensitized lymphocytes
against an antigen that mediates a number of chain reactions.
The local toxicity of anaesthetics is not to be underestimated:
ischaemic necrosis of tissues can, in fact, follow the injection of
the anaesthetic. It may be due to the irritation given by the
solution or by the vasoconstrictor effect of adrenaline.
Absolute contraindications to the use of anaesthetics are allergy
medications, infections at the site of administration, vascular
malformations at the site of application and pregnancy. Relative
contraindications are severe patient conditions, haemophilia,
leukemia, severe diabetes mellitus etc., which should be evalu-
ated from time to time in each individual patient.5–8
STEROIDS
Pharmacological aspects
Steroids are anti-inﬂammatory drugs of endogenous synthesis
with different effects. They have an effect on the glucose me-
tabolism, ﬂuid and electrolyte balance and pituitary gland, with
a negative feedback mechanism, and have an anti-inﬂammatory
and immunosuppressive effect.9
They can be classiﬁed into mineralocorticoids (e.g. aldosterone),
which control the sodium and water balance, and glucocorticoids
(e.g. cortisol),10 which control the glucose metabolism and in-
ﬂammation. Their action mechanism includes reduction of in-
ﬂammation by lowering capillary vasodilatation and vascular
permeability. This leads to reduction in the chemotaxis of poly-
morphonuclear cells and macrophages and reduction in the re-
lease of vasoactive kinins. Their anti-inﬂammatory effect is carried
out by action on a nuclear receptor targeting a DNA sequence
called the glucocorticoid-responsive element, helping to block the
synthesis of many cytokines.11,12
When and how
Understanding the pharmacological features of steroids can help
in the choice of those to use. Triamcinolone acetonide is a cor-
ticosteroid; it is one of the least soluble corticosteroids with an
extended effectiveness of about 14 days compared with 8 days of
methylprednisolone acetate. Among the most used injectable
steroids are methylprednisolone acetate, triamcinolone acetonide
and triamcinolone hexacetonide. The methylprednisolone, which
is an anti-inﬂammatory glucocorticoid, is usually employed for
patients with rheumatic pathologies and for disturbances of
the small joints. It is also used in case of acute pain owing to its
quick effect on symptomatology.12,13 Steroids are typically used
before any other treatment when the areas to be treated present
inﬂammation.12–16 Their administration can precede inﬁltrative
treatments of the Achilles or patellar tendons,13 in the presence
of inﬂammation of the tendon sheath.11,13 They can precede an
intra-articular inﬁltrative treatment of the knee17,18 and hip, if
there is joint effusion.19–21 In the shoulder, they can also be used
in case of calciﬁc tendonitis to reduce severe pain as quickly
as possible.22 This kind of treatment has several limitations and/or
contraindications related, for example, to the presence of patients
with diabetes or allergy or professional athletes.23 As for imaging,
pre- and post-treatment ultrasounds and/or MRI examinations
show disappearance or reduction of bursitis or peritendineous
inﬂammation. When treating the underlying or associated dis-
eases (tendinosis or partial lesions), however, no signiﬁcant
clinical and functional beneﬁts are observed.
Complications
The literature9,11,13,24 describes rare side effects of injected cor-
ticosteroids, such as involvement of the joint (infection, steroid
arthropathy and post-injection ﬂare) and the surrounding soft
tissues (asymptomatic pericapsular calciﬁcation, subcutaneous
fat or skin atrophy/depigmentation and tendon rupture). Sys-
temic effects are also described, such as facial ﬂushing, vasovagal
reaction or hypersensitivity reactions. The most feared is septic
arthritis, which is extremely rare. In patients with diabetes, the
control of blood glucose level is necessary in case of repeated
steroid injections. An increase of blood glucose was reported in
patients treated with soft tissues or peritendineous inﬁltrative
procedure.13,24 Great attention is necessary in case of patients
with bacteraemia, sepsis, skin lesion at the site of the injection,
coagulopathy pathologies or joint prostheses.
PLATELET-RICH PLASMA
Pharmacological aspects
The platelet-rich plasma (PRP) is obtained by withdrawing blood
directly from the patient, with a needle of 18–20G, to avoid
trauma to the platelets, which if damaged would release their
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growth factors early.25–28 The syringe contains an anticoagulant
(ratio of sodium citrate and blood, 1 : 9) in order to chelate cal-
cium, block the coagulation cascade and preserve the growth
factors. The blood is subsequently submitted for centrifugation
and cell-separation processes to obtain a new substance richer in
platelets. After centrifugation, a composite laminate is obtained,
consisting of red blood cells, platelet-poor plasma and PRP.
Usually, the volume of PRP obtained is 1/10 of the volume of the
whole blood (6ml per 60ml of blood drawn or 3ml per 30ml of
the ﬂuid). Sodium bicarbonate is added (about 0.05ml of sodium
bicarbonate for each millilitre of PRP) to buffer the acidity results
from platelet metabolism; an excessive pH decrease could jeop-
ardize the viability of the platelets.26,27 Once injected at the in-
jection site, the platelets will activate when they come into contact
with substances such as collagen Type I or through paracrine
mechanisms related to the release of platelet-activating factors
from previous elements lysed by trauma incurred during han-
dling.28 The PRP may be injected in this form after further acti-
vation with either calcium gluconate or sodium bicarbonate. The
activation leads to a faster release of growth factors; the possibility
of activating PRP also depends on the intended use.29 The main
advantages of PRP are safety (directly taken from the patient’s
own blood). In this way, the risk of contracting communicable
diseases such as hepatitis is avoided.30 Another advantage of PRP
is its cost effectiveness, especially compared with the costs of
producing artiﬁcial tissues. The mechanisms of action of PRP are
not fully known yet, but are believed to be related to a slow
continuous release of growth factors present in abundance in the
platelet gel. The action mechanisms of the best-known platelet
growth factors are brieﬂy exposed below.25,28,31,32
The platelet-derived growth factor has a mitogenic action (it
induces mitosis or cell replication) and induces angiogenesis; it
also coordinates the action of other growth factors.
The transforming growth factor-b is a protein with many
functions, including the stimulation of osteoblasts and ﬁbro-
blasts and the inhibition of osteoclasts.
The insulin-like growth factor I/II acts by stimulating the pro-
duction of osteoblasts and acting on precursors of the latter; they
also stimulate the deposition of the bone matrix.
The basic ﬁbroblast growth factor works by stimulating the mi-
gration of ﬁbroblasts and collagen synthase. It is the growth factor
that plays the most interesting role in the ﬁeld of aesthetic medicine.
The epidermal growth factor works by stimulating the mesen-
chymal and epidermal cells.
When and how
The growing interest in the use of blood derivatives such as PRP
in the joint diseases is due to the release of the growth factors
contained in platelets that have anti-inﬂammatory and re-
generative capacity.25,27,28,33–36 The use of PRP under ultrasound
guidance, in the treatment of degenerative processes34 and ar-
thritic knee and hip, is efﬁcient in terms of reduction of pain and
recovery of functionality.35–39 The platelet gel exerts an anti-
inﬂammatory action related to the chemotactic activity towards
the cells of inﬂammation and promotes true tissue regeneration
due to the activation of growth factors.40 This should lead at the
local level to a reduction of the inﬂammatory phenomena, with
effects on pain, and to a partial tissue restoration. Thanks to its
regenerating capacity, PRP can also be used in degenerative dis-
eases and in case of partial tendon lesions. In these cases, it is
injected directly into the tendon structure41,42 in a single site (in
case of partial lesions) or in multiple locations of the tendon in
case of diffuse degeneration.43 Usually, in clinical practice, PRP is
used for tendinosis or partial lesions of tendons such as
supraspinatus41,44 (Figure 1), Achilles tendons45 and patellar
tendons46–48 (Figure 2) or for epicondylitis,49–51 sports muscle
injuries52 and ﬂexor/extensor tendons of the hand.42
Patient recruitment is carried out using diagnostic imaging modal-
ities. With them, it is possible to carry out a more accurate evaluation
of arthritis or tendinopathy and to make a qualitative as well as
quantitative comparison before and after the treatment.41–44,46,53
Complications
Sometimes, pain after treatment was observed, but it responded
to analgesics or systemic anti-inﬂammatories. Possible side effects
of PRP injection treatments are divided into absolute and relative.
The ﬁrst group includes septic arthritis, overlying cellulitis, ad-
jacent osteomyelitis, haemodynamic instability or septicaemia,
critical thrombocytopenia, platelet dysfunction syndrome and
cancer (mostly haematopoietic or bone cancer). Other compli-
cations are allergic reactions, skin discolouration or blood clots.
Some authors describe adhesive capsulitis and tendon rupture, in
case of intratendinous injection.37,38,41–43,45,47,49,52,54
HYALURONIC ACID
Pharmacological aspect
Hyaluronic acid (HA) is a glycosaminoglycan, one of the main
components of the extracellular matrix. It is a polymer of high
molecular weight (several million Dalton), consisting of units of
glucuronic acid and N-acetylglucosamine bound together by
glycosidic bridges. It is produced by synovial cells of Type B and
ﬁbroblasts through HA synthase and is then released into the
synovial ﬂuid. Its catabolism takes place in the synovial ﬂuid by
hyaluronidase. HA has viscoelastic properties; it allows lubrica-
tion, regulates the permeability to nutrients and protects the
tissue by inﬂammatory cells.55
When and how
The exact mechanism of action of exogenous HA is not known,
but it seems that it may act through a dual mechanism:
• direct mechanical protection of the joint surface through the
articular surface
• indirectly through many metabolic effects, including the
induction of endogenous HA production (viscoinduction), the
reduction of the presence of inﬂammatory cells in the synovial
ﬂuid and the possible stimulation of the proliferation and
differentiation of chondrocytes.
The mechanism of action of exogenous HA is greatly inﬂuenced
by its molecular weight: the biological activity prevails in the
low/average molecular weight while the rheological and anal-
gesic activities prevail in the high molecular weight. HA for
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intra-articular use is produced in two ways: bacterial fermen-
tation and puriﬁcation, and extraction and puriﬁcation from
rooster combs. The products thus obtained can be modiﬁed by
cross-linking to increase the molecular weight of the product.
The differences in the technique of production result in a different
molecular weight of the product and, according to some
authors,35,55,56 even in a different clinical efﬁcacy. Some authors
have attributed the greater clinical effect to the HA of a high
molecular weight on the basis of in vitro studies; but, the hetero-
geneity of the results do not allow precise statements about it.35,55,56
Complications
Despite the commercial products ﬁnding wide use, clinical
studies have shown that in some cases (from 1 to 11% of cases),
Figure 2. The sagittal plane on the T1 (a) and STIR (b) images demonstrate Achilles tendinopathy at the level of the insertional area
(white arrows); the sagittal plane on the T1 (c) and STIR (d) images are showing the results after platelet-rich plasma treatment with
reduction of the thickness of this area (white arrows).
Figure 1. The top image on the left (a) is showing the hypoechoic focal area of tendinopathy at the level of the insertional portion of
the supraspinatus tendon (white arrow); in the middle (b) and on the right (c), T1 and T2 weighted images of the same lesion (black
arrows) are shown. The bottom images report the good results obtained after platelet-rich plasma treatment at both the ultrasound
(d) and MRI (e, f) examinations with the reduction of the lesion [white arrow in (d) and black arrows in (e, f)].
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in the 24–48 h following the intervention of viscosupplementa-
tion, the patient develops inﬂammatory reactions with the ap-
pearance of transient pain in the interested articulation, swelling
and erythema. It has not been established what are the causes of
such post-injection synovitis that does not occur frequently after
the ﬁrst surgery, but whose frequency increases considerably
after the second injection and in subsequent cycles. Some
authors35,55,56 attribute it to the injection technique, but there is
no evidence to support this claim; it is more likely that it
depends on the foreign body reaction or hypersensitivity to
certain protein components present in the product injected.
Systemic effects related to the administration of HA have rarely
emerged and are represented by rash, hives, itching, fever,
nausea, headache, dizziness, chills, muscle cramps, paraesthesia,
peripheral oedema, face oedema and malaise. HA should not be
used in patients with known hypersensitivity and in the presence
of severe infections, inﬂammations or skin diseases. It should
not be used if there is articular joint effusion or in the presence
of venous stasis.35,55,56
OXYGEN–OZONE
The oxygen–ozone (O2–O3) therapy is based on the application
of a mixture of 97% of medical oxygen (O2) and 3% ozone (O3).
Ozone is an inorganic molecule, discovered in 1832 by Christian
Friedrich Scho¨nbein. He described the strong odour during the
slow oxidation experiments of white phosphorus and the elec-
trolysis of water, and, in 1839, he named this molecule ozone.
In 1857, von Siemens demonstrated that ozone can be produced
by the passage of oxygen through an electric arc, thus building
the ﬁrst ozone generator. Ozone is found in large quantities in
the atmosphere, about 25 km from the earth surface, where it
is able to absorb ultraviolet rays from the sun, protecting this
planet from their harmful action. Minor amounts of ozone
are also present in the lower atmosphere (ozone is an essential
component of smog), but this type of ground-level ozone is a
pollutant and can be poisonous if inhaled in large doses.57
Ozone is highly unstable: in gaseous form at 20 °C, its half-life is
3 days, while in liquid form, in addition to being an explosive, its
half-life is 20min. This means that it cannot be stored but must
be produced just before use. It is produced by an endothermic
reaction of oxygen molecules in the vicinity of an electric shock
and lightning through the reaction 3O2→ 2O3.
57
When and how
Ozone is used in both the industry and medical ﬁeld and in the
latter case, it is used after being mixed with oxygen (constituting
the medical ozone O2–O3). The ozone therapy is being practised
since World War I, when it was applied to wounds in order to
avoid amputation for gangrene; but, only in recent years, more
detailed studies have appeared on its effect. The systems cur-
rently used for the production of ozone are based on the patent
of an ozone generator, now known as the “Siemens Type”
generator, designed by Werner von Siemens in 1857. Welsbach,
in fact, used cells made of two concentric electrodes separated by
a gap of a few fractions of a millimetre (about 0.5–0.8mm)
through which oxygen passes. The two electrodes have a voltage
difference of about 7–30 kV. The internal metallic electrode is
connected to a medium voltage generator, while the external
electrode, which is made of glass or ceramic, is connected to the
ground. There is also a cooling system that removes the heat
generated by the reaction of medical ozone formation. The
voltage difference between the two electrodes allows splitting of
oxygen molecules and the formation of ozone molecules. After
the production, the mixture of oxygen–ozone is conveyed to-
wards two routes; the ﬁrst available to the operator with the aid
of a syringe. The second route, however, destroys the unused
mixture. Ozone is a strong irritant gas, is colourless, oxidizes, is
more reactive than oxygen and is able to split unsaturated
substances, forming the reactive oxygen species. If the oxidative
stress lasts for a short time, the antioxidant systems of the body
fail to lock it by the activation of glutathione, superoxide dis-
mutase etc. with detoxifying action. If the oxidative stress persists
owing to chronic conditions or in the presence of antioxidant
system deﬁcits, it causes cellular damage. Ozone plays an anal-
gesic and anti-inﬂammatory action through the inhibition of
cyclooxygenase, stimulation of the metabolism of histamine and
monoamine oxidase with reduction of vasodilation and muscle
hypertonicity. The medical ozone determines the increase of
glycolysis, lipolysis and platelet reduction increasing the blood
concentration of 2,3-bisphosphoglycerate (2,3DPG), which
results in eutrophic, anti-inﬂammatory and analgesic effects,
with greater ﬂow of blood and oxygen to the tissues. Through
stimulation of production and release of cytokines and inter-
ferons, it has immunomodulatory effects. Actually, the typical
way to use ozone is chemiodiscolysis: in fact, the use of ozone
therapy is a treatment option that is used to treat intervertebral
disc extrusion where conservative therapies and/or surgery are
not indicated. O2–O3 is rarely injected at the level of the joint or
in the tendons, and the therapeutic effects are similar if not lower
than those obtained using other drugs such as steroids. There are
no contraindications to the use of ozone; but, attention must be
paid to some patient conditions such as pregnancy, hyperthy-
roidism, severe cardiovascular diseases and heart failure.57–59
Complications
Among the side effects of ozone, the effects based on the O2–O3
mixture must be distinguished from those based on the ad-
ministration technique. Among the ﬁrst, a spectrum of sit-
uations can be observed, ranging from the simple feeling of
heaviness or burning at the injection site to a real vagal crisis.
Among the adverse effects based on the technique of adminis-
tration, there can be lesions created by the needle during its
penetration: haematoma, injury to small blood vessels, pain and
sensitivity disorders in the nerve roots and discitis due to a non-
sterile procedure. All these events, however, are rare and can be
avoided through compliance with good procedures.59
OTHER DRUGS AND AGENTS USED
Prolotherapy
It consists in injecting hyperosmolar dextrose into the area of
tendinosis.60 Dextrose is an irritant drug which may act in two ways
to relieve pain: causing inﬂammation with the release of growth
factors, or creating tissue regeneration acting as a sclerosing factor
to vascular tissue.61
Whole blood
It is obtained directly from the patient. Peripheral blood is taken
from the patient and reinjected into the pathologic tendon.
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Platelets contained in autologous blood can increase the release
of growth factors at the injection site.62 Compared with whole
blood, PRP contains, after centrifugation, a greater concentra-
tion of platelets and induces more rapid release of growth fac-
tors. However, this is still the subject of studies. Both types of
injections are often combined with needling.63,64
Tendon fenestration or needling
It consists in inserting a needle into the pathological area,
without injecting drugs. Also in this case, the use of an ultra-
sound probe is necessary to ensure the proper placement of the
needle at the level of the area to be treated without puncturing
adjacent structures. This technique consists in repeatedly in-
troducing a needle into the diseased area, creating a bleeding at
that level of the tendon structure and inducing an inﬂammation
with the release of growth factors and other substances, which
stimulate the process of healing. In literature, there are many
studies describing this technique as effective in the treatment of
epicondylitis, and also in the treatment of the patellar and
Achilles tendons diseases.65
DISCUSSION AND CONCLUSION
Diagnostic imaging modalities have proven to be very useful in
clinical practice to evaluate a wide range of musculoskeletal
pathologies.66–77 The use of diagnostic imaging techniques
such as ultrasound, CT and MRI to guide or to verify the
effect of musculoskeletal intervention is also widespread.78–82
Inﬁltrative therapies employed in interventional musculoskeletal
radiology are very effective and versatile clinical therapeutic
tools.1,2,4,8,9,25,34,43,56 The drugs for US-guided inﬁltrative ther-
apy have been used since the beginning of the twentieth century,
but they have also been used in previous years in many different
ﬁelds of medicine such as orthopaedics, rheumatology, physi-
atrics etc.25,32,34,43,56 Until a few years ago, owing to poor
availability and poor knowledge of pharmacological effects, only
a few drugs (anaesthetics and steroids)5,8,9 were been used. New
imaging technologies, advancements in diagnostic equipment
and knowledge of joint diseases in addition to the discovery and
introduction of new drugs (HA and PRP)27,34,35,37,41,43,52,55 in
the past years have enabled the development of a modern dis-
cipline that combines knowledge and technology for the treat-
ment of joint diseases. Currently, a broader ﬁeld of action is
possible in the ﬁeld of musculoskeletal pathologies whose
treatment was unthinkable only a few years ago. Aided by im-
aging, it is possible to accurately achieve the site to be treated
with a small margin of error, following in real time every step of
the procedure. The availability of a variety of new drugs provides
expansion of the indications and therapeutic possibilities, with
resolution of pain and maximum therapeutic outcome. The
patient comes for observation, is submitted to clinical exami-
nation with assessment of pain and function and subsequently
undergoes ultrasound scan and MR for a proper assessment of
Figure 3. In the T1 weighted image (a) and the STIR image (b), the coronal planes are showing the femoral and tibial chondral
damages (white arrows) on the lateral side, with joint effusion in the anterior recess on the axial plane (c). After platelet-rich plasma
treatment, the coronal MR images are demonstrating the disappearance of the chondral damages in (d, e) (coronal planes) and the
reduction of the joint effusion in (f) (axial plane).
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the joint pathology. In most cases, pain is related to an in-
ﬂammatory process secondary to the underlying disease. The
patient is initially treated with steroids to reduce inﬂammation.
Steroids can be injected only into the recess joint or the tendon
bursa but not directly into the tendon structures or into the
muscle. McCabe et al,83 in a recent review, reported a reduction
in pain after steroid injection at 3–4 weeks post-treatment in all
cases, with a marked reduction after 1 week; they also put at-
tention on the effectiveness of the steroid treatment, but em-
phasized on the poor quality of the evidence reported. Once
inﬂammation is resolved, treatment of the underlying disease
can start. In a randomized trial, Sun et al5 demonstrated that
patients treated with systemic non-steroidal anti-inﬂammatory
drugs did not obtain results for pain relief and functional im-
provement. Over the past few years, the use of blood derivatives
has become increasingly important in the treatment of muscu-
loskeletal diseases. Signiﬁcant results have been obtained with
the in situ application of PRP to induce tissue regeneration in
degenerative diseases affecting the joints and tendons. Good
results are described in literature regarding the use of PRP in the
treatment of degenerative tendon diseases,1,33,34,37,38,43 such as
rotator cuff tendinosis41–44 or plantar fasciitis, and in particular
the insertional tendon disease of the Achilles45 and patellar
tendons.46–48 Wilson et al84 evaluated, after PRP intratendinous
injection, the intratendinous retention and distribution of the
injected substance, tissue morphology following injection and
effect of intratendinous injection and fenestration, demon-
strating how PRP is not only feasible but also remains in the
tendon after the procedure with slight loss outside the tendon.
In another study, Wesner et al85 observed that patients treated
with PRP for degenerative tendinopathies obtained clinical ef-
ﬁcacy and improvement of tendon lesions at MRI compared
with the control group. Some authors also focus on the im-
portance of employing PRP in the treatment of osteoarthritis of
the knee31,34,35,37,38,40 to reduce joint inﬂammation and to delay
degenerative processes of the cartilage (Figure 3). These results
are also reported by Meheux et al,86 who described differences
in terms of pain, stiffness and physical function, comparing
patients treated with PRP with those treated with HA.
In conclusion, on the basis of critical literature review, the
clinical data considered in terms of reduction of pain, functional
recovery and morphological recovery suggest that the use of
steroids in combination with PRP may be a good therapeutic
alternative treatment in tendon and extremity joint degenerative
and inﬂammatory diseases.
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